Trial *
Publication Montalvan E, Chest (2021) (published paper)
Dates: 2020-09-01 to 2020-10-31
Funding: Not reported/unclear
Conflict of interest: No
| Methods | |
| RCT Blinding: Unblinded | |
| Location :
Single center / Honduras Follow-up duration (days): * | |
| Inclusion criteria |
|
| Exclusion criteria | NR |
| Interventions | |
| Treatment
DEX low dose 8 mg/day |
|
| Control
DEX high dose 24 mg/day | |
| Participants | |
| Randomized participants : DEX high dose=41 DEX low dose=40 | |
| Characteristics of participants N= 81 Mean age : NR 46 males Severity : Mild: n=* / Moderate: n=* / Severe: n=* Critical: n=* Number of vaccinated participants: NR | |
| Primary outcome | |
| In the register NR | |
| In the report Reduction in mortality and intubation. | |
| Documents available |
Protocol NR Statistical plan NR Data-sharing willing stated in the publication: Not reported |
| Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
* |
| General comment | Only the conference abstract was available for use in data extraction and assessment of risk of bias. No registry, protocol or statistical analysis plan was available. Mortality was reported (6 in the high-dose group and 2 in the low-dose group), but with no time point reported, so no data were extracted. |